These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Tendencies in the etiopathogenesis of glaucoma--present and future]. Călugăru D; Călugăru M Oftalmologia; 2008; 52(3):10-22. PubMed ID: 19149112 [TBL] [Abstract][Full Text] [Related]
24. Too thick for your drugs. Dreyer EB Am J Ophthalmol; 2004 Nov; 138(5):847-8. PubMed ID: 15531322 [No Abstract] [Full Text] [Related]
25. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Konstas AG; Mikropoulos D; Haidich AB; Ntampos KS; Stewart WC Br J Ophthalmol; 2009 Apr; 93(4):481-5. PubMed ID: 19019932 [TBL] [Abstract][Full Text] [Related]
26. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma. Polo V; Larrosa JM; Ferreras A; Borque E; Pablo LE; Honrubia FM Ann Ophthalmol (Skokie); 2008; 40(3-4):157-62. PubMed ID: 19230353 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma. Mandić Z; Bojić L; Novak-Laus K; Sarić D Coll Antropol; 2002 Dec; 26(2):595-600. PubMed ID: 12528287 [TBL] [Abstract][Full Text] [Related]
28. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. Yildirim N; Sahin A; Gultekin S J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382 [TBL] [Abstract][Full Text] [Related]
29. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Caprioli J; Coleman AL Ophthalmology; 2008 Jul; 115(7):1123-1129.e3. PubMed ID: 18082889 [TBL] [Abstract][Full Text] [Related]
30. Diuretics, placebos, and the European glaucoma prevention study. Mills RP Am J Ophthalmol; 2007 Aug; 144(2):290-1. PubMed ID: 17659959 [No Abstract] [Full Text] [Related]
31. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma. Maruyama K; Shirato S; Haneda M Jpn J Ophthalmol; 2005; 49(1):61-2. PubMed ID: 15692779 [No Abstract] [Full Text] [Related]
32. [Ocular structural and functional disturbances, typical for open-angle glaucoma, are the basis for the development of its present-day classification]. Volkov VV Vestn Oftalmol; 2005; 121(4):35-9. PubMed ID: 16223043 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients. Chiselită D; Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041 [TBL] [Abstract][Full Text] [Related]
38. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391 [TBL] [Abstract][Full Text] [Related]
39. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Tamer C; Oksüz H Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574 [TBL] [Abstract][Full Text] [Related]
40. [Comparative analysis of life quality in patients receiving beta-blockers and xalathane (latanoprost)]. Tugushi OA; Shliapuzhnikova AV; Listopadova NA Vestn Oftalmol; 2005; 121(4):41-3. PubMed ID: 16223045 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]